Overview and Highlights 

The first half of 2026 marked biopharma's strongest dealmaking period since before the pandemic, with more than $130 billion in M&A across 30+ billion-dollar transactions. Facing looming patent cliffs, large pharma increasingly paid premium prices for late-stage, de-risked assets rather than relying on internal pipelines. Major acquisitions included Boston Scientific & Penumbra ($14.5B), Sun Pharma & Organon ($11.75B), Merck KGaA & Bio-Techne ($11.3B), AbbVie & Apogee Therapeutics ($10.9B), GSK & Nuvalent ($10.6B), and Vertex & Crinetics ($10B). Eli Lilly led activity with over $25 billion across five acquisitions, while Gilead completed three deals totaling $14.8 billion.

Two themes defined the period. First, competition intensified in cell and gene therapy, highlighted by Lilly's acquisitions of Orna Therapeutics and Kelonia Therapeutics, reflecting growing interest in in vivo CAR-T platforms. Second, psychedelic-inspired neuroscience entered the mainstream, with Lilly and Otsuka making major investments in next-generation treatments for depression and PTSD. Financing momentum matched M&A activity: Kailera Therapeutics and Parabilis Medicines completed record biotech IPOs, while Blackstone raised a $6.3 billion life sciences fund. The pace continued into late July with KKR's $5.7 billion acquisition of Integer Holdings and Curium's up-to-$8 billion agreement for Lantheus, leaving 2026 on track to become biopharma's biggest dealmaking year since 2019.

‍

‍

‍

>$5B M&A Deals

1 | Boston Scientific Acquires Penumbra | Diagnostics

Boston Scientific has agreed to acquire Penumbra, a thrombectomy device maker, in a cash-and-stock transaction valued at approximately $14.5 billion, marking the largest healthcare deal announced in the opening weeks of 2026. Boston Scientific will pay $374 per share, funding the deal with roughly $11 billion in cash and the remainder in stock. The acquisition adds Penumbra's thrombectomy and aspiration platform to Boston Scientific's structural heart and interventional portfolios, consolidating two of the leading players in mechanical clot removal. The deal set an aggressive early tone for 2026 dealmaking, with a string of multi-billion-dollar transactions following in its wake through the rest of H1.

2 | Sun Pharma Acquires Organon for $11.75B, Its Largest-Ever Deal | Pharma

Sun Pharmaceutical Industries has agreed to acquire Organon in an all-cash transaction valued at $11.75 billion, paying $14.00 per share (a 24% premium to Organon's prior closing price). The deal is the largest biopharma transaction of 2026 to date and the largest-ever acquisition by an India-based drugmaker, pushing Sun's combined revenue to roughly $12.4 billion and placing it among the top 25 global pharma companies. The acquisition reflects a broader mid-year theme of scale-driven consolidation, as mid-sized players use M&A to leapfrog into the industry's upper tier rather than grow organically. The transaction is expected to close in early 2027, pending regulatory and shareholder approval.

3 | Merck KGaA Acquires Bio-Techne for $11.3B | Diagnostics

Merck KGaA has agreed to acquire Bio-Techne for $73 per share in cash, valuing the life-sciences tools and diagnostics company at approximately $11.3 billion. The acquisition is a 24% premium and Merck KGaA's largest deal since its Sigma-Aldrich acquisition. Bio-Techne's protein sciences, spatial biology, and diagnostics businesses supply reagents, instruments, and clinical products used across cell and gene therapy research and bioprocessing. The deal significantly deepens Merck KGaA's footprint in the life-sciences tools space, an area of continued consolidation. Announced June 25, 2026, the transaction is expected to close in late 2026 or early 2027.

4 | AbbVie Acquires Apogee Therapeutics for $10.9B | Biotech

AbbVie has agreed to acquire Apogee Therapeutics for $135.11 per share in cash, valuing the clinical-stage biotech at approximately $10.9 billion in AbbVie's largest buyout in more than five years. The deal centers on zumilokibart, an IL-13-targeting antibody for atopic dermatitis and asthma designed for dosing as infrequently as once every six months, providing a potential edge over Sanofi and Regeneron's Dupixent. The acquisition deepens AbbVie's push into next-generation immunology as it works to offset Humira's continued erosion. The transaction is expected to close in the third quarter of 2026.

5 | GSK Acquires Nuvalent for $10.6B to Rebuild Oncology Pipeline | Biotech

GSK has agreed to acquire Nuvalent for $10.6 billion, paying $124 per share in cash (a 40% premium) to secure a clinical-stage lung cancer pipeline built around genetically defined targets (e.g., ROS1, ALK, and an early-stage HER2 program). It's GSK's second-largest deal in company history, trailing only its 2014 vaccines swap with Novartis. The move is part of a broader race among big pharma to shore up oncology and rare-disease pipelines ahead of looming patent cliffs. GSK faces a steep revenue drop when its top-selling HIV drug loses exclusivity starting in 2028. Both of Nuvalent's lead assets have been fast-tracked by the FDA and could reach approval before year-end.

6 | Vertex Acquires Crinetics Pharmaceuticals for $10B, Its Largest-Ever Deal | Biotech

Vertex Pharmaceuticals has agreed to acquire Crinetics Pharmaceuticals for $85.00 per share in an all-cash deal valuing the endocrine-disease specialist at roughly $10 billion. The acquisition is Vertex's largest to date. The deal adds Palsonify, an oral therapy for acromegaly, and atumelnant, a Phase 3 candidate for congenital adrenal hyperplasia, both built around genetically defined hormonal pathways with a combined peak sales estimate above $5 billion. The acquisition marks Vertex's clearest move yet beyond its historic cystic fibrosis franchise and into a broader precision-endocrinology strategy. Crinetics shares more than doubled on the announcement, and the deal is expected to close in the third quarter of 2026.

7 | Eli Lilly Acquires Centessa Pharmaceuticals for up to $7.8B | Biotech

Eli Lilly has agreed to acquire Centessa Pharmaceuticals for up to $7.8 billion at $38 a share upfront (about $6.3 billion) plus up to $9 a share in milestones to secure a pipeline of orexin receptor agonists for sleep-wake disorders. Centessa's lead candidate, cleminorexton, has shown a potential best-in-class profile across narcolepsy type 1, narcolepsy type 2, and idiopathic hypersomnia in Phase IIa studies. The deal expands Lilly's neuroscience franchise into a validated but underserved mechanism, part of a dealmaking streak that made Lilly the most acquisitive company in biopharma through the first half of 2026. Cleared by the UK's High Court in June, the transaction is closed.

8 | Gilead Completes $7.8B Acquisition of Arcellx | Biotech

Gilead Sciences completed its largest deal to since 2020 with the acquisition of Arcellx for approximately $7.8 billion at $115 per share in cash plus a $5 contingent value right. The acquisition gives Gilead full ownership of anito-cel, an experimental CAR-T therapy for multiple myeloma developed in partnership with Kite, ahead of its potential commercial launch. It's the first of three acquisitions Gilead struck in 2026, part of a broader push to build out its oncology and inflammation pipelines through cell-therapy and next-generation biologics platforms. The deal closed on April 28, 2026.

9 | Eli Lilly Acquires Kelonia Therapeutics for up to $7B | Biotech

Eli Lilly will acquire Kelonia Therapeutics in a deal worth up to $7 billion, paying $3.25 billion upfront with the balance tied to clinical, regulatory, and commercial milestones. Kelonia's in vivo CAR-T technology reprograms a patient's T-cells inside the body, eliminating the costly ex vivo harvesting and manufacturing steps required by current cell therapies. Lilly plans to apply the platform beyond multiple myeloma to other blood cancers and potentially solid tumors, marking its second in vivo cell-therapy bet of the year after Orna Therapeutics. The deal is expected to close in the second half of 2026.

10 | Merck Acquires Terns Pharmaceuticals for $6.7B | Biotech

Merck agreed to acquire Terns Pharmaceuticals for $53 per share in cash, valuing the clinical-stage oncology company at approximately $6.7 billion. The deal secures TERN-701, a novel oral BCR::ABL1 tyrosine kinase inhibitor in Phase 1/2 testing for chronic myeloid leukemia, adding a differentiated hematology asset as Merck works to diversify ahead of Keytruda's 2028 patent cliff. It's Merck's third multibillion-dollar acquisition over the past year. The acquisition closed on May 5, 2026.

‍

‍

‍

<$5B M&A Deals

1 | Gilead Acquires Tubulis for up to $5B | Biotech

Gilead will pay $3.15 billion upfront, plus up to $1.85 billion in milestones, to acquire Tubulis and its antibody-drug conjugate platform, making its third acquisition of 2026. The deal brings two clinical-stage ADCs, TUB-040 and TUB-030, into Gilead's oncology pipeline, built on a next-generation linker-payload technology designed to widen the therapeutic window versus earlier-generation ADCs. The acquisition reflects the continued resurgence of ADCs as a modality of choice for large-molecule dealmaking in 2026. The transaction was finalized in May of 2026.

2 | Novartis Acquires Pikavation Therapeutics for up to $3B | Biotech

Novartis agreed to pay $2 billion upfront and up to $1 billion in milestones to acquire Pikavation Therapeutics, a subsidiary of Synnovation, gaining a portfolio of pan-mutant-selective PI3Kα inhibitors led by SNV4818. The program targets breast cancer and other solid tumors defined by specific PI3K pathway mutations, reinforcing Novartis's biomarker-driven oncology strategy. The deal agreement was announced March 20, 2026, and has not closed yet.

3 | Eli Lilly Acquires AtaiBeckley for $2.8B, Entering Psychedelic Medicine | Biotech

Eli Lilly agreed to acquire AtaiBeckley for $6.75 per share in cash (about $2.8 billion), plus up to $2.50 per share in contingent value rights, marking its entry into psychedelic-derived medicine. The deal secures BPL-003, a synthetic 5-MeO-DMT analog in Phase 3 development for treatment-resistant depression, and VLS-01, an earlier-stage asset for social anxiety disorder. It's Lilly's fifth acquisition disclosed in 2026, extending its neuroscience buildout into a fast-emerging category of rapid-acting mental health treatments. The deal is expected to close in the third quarter of 2026.

4 | Eli Lilly Acquires Orna Therapeutics for up to $2.4B | Biotech

Eli Lilly agreed to acquire Orna Therapeutics for up to $2.4 billion, gaining an in vivo CAR-T platform led by ORN-252, a CD19-targeting therapy in development for B-cell-driven autoimmune disease. Unlike conventional CAR-T, Orna's approach reprograms immune cells directly inside the body using circular RNA technology, avoiding the need for cell harvesting and ex vivo manufacturing. The deal, announced February 9, 2026, was Lilly's first move into in vivo cell therapy this year and a preview of the Kelonia deal that followed two months later.

5 | Argenx Acquires Forte Biosciences for $2.2B | Biotech

Argenx agreed to acquire Forte Biosciences for approximately $2.2 billion in cash at $77 per share, an 86% premium to secure FB102, a first-in-class anti-CD122 antibody. The move followed positive Phase 1b vitiligo data announced just weeks earlier, and the asset also carries potential in celiac disease and other autoimmune conditions. The deal converts what began as a strategic investment into a full acquisition, reflecting how quickly clinical readouts can accelerate M&A in the current market.

6 | Gilead Acquires Ouro Medicines for up to $2.175B | Biotech

Gilead agreed to acquire Ouro Medicines for approximately $2.175 billion to add gamgertamig (OM336), a clinical-stage BCMAxCD3 T-cell engager, to its inflammation pipeline. The deal, Gilead's second of three 2026 acquisitions, extends the company's push beyond its core virology and oncology franchises into autoimmune disease, using a T-cell engineering approach originally developed for cancer. Gilead and its subsidiary Lakefront completed the acquisition on June 4, 2026.

7 | Novartis Acquires Excellergy for up to $2B | Biotech

Novartis agreed to pay up to $2 billion to acquire Excellergy and its lead candidate, EXL-111, an early-stage anti-IgE therapy designed as a potential successor to Xolair. The deal builds on Novartis's existing allergy franchise with a next-generation trifunctional effector cell response inhibitor, aiming to improve on the efficacy of first-generation anti-IgE biologics. Announced March 27, 2026, the deal was Novartis's second multibillion-dollar deal in a single week.

8 | Samsung Biologics Bids $1.8B for PolyPeptide Group | Pharma Service

Samsung Biologics made an all-cash offer worth about $1.8 billion (CHF 1.46 billion) to acquire Switzerland's PolyPeptide Group, a contract manufacturer specializing in peptide therapeutics. The deal, the largest takeover in South Korean biopharma history, gives Samsung Biologics manufacturing capacity for GLP-1 and other peptide-based drugs, extending its CDMO business beyond biologics into small-molecule peptide production. The offer represents a 6.1% premium to PolyPeptide's prior closing price.

9 | Tempus AI Acquires Personalis for $1.5B | Diagnostics

Tempus AI agreed to acquire the roughly 90% of Personalis it doesn't already own for $16.25 per share, a deal valuing the cancer-monitoring company at about $1.5 billion in an all-stock transaction. The acquisition combines Personalis's NeXT Personal minimal-residual-disease (MRD) testing technology, which uses whole-genome sequencing to build a patient-specific tumor signature, with Tempus's AI-driven oncology data platform. The companies had an existing commercial relationship dating to 2023, when Tempus first took a stake in Personalis. Closing is expected in late 2026 or early 2027.

10 | Otsuka Acquires Transcend Therapeutics for up to $1.225B | Pharma

Otsuka Pharmaceutical agreed to acquire Transcend Therapeutics for up to $1.225 billion ($700 million at closing plus up to $525 million in sales-based milestones) adding a next-generation PTSD therapy to its neuropsychiatry pipeline. The deal centers on TSND-201 (methylone), a rapid-acting treatment that posted favorable Phase 2 results published in JAMA Psychiatry in February 2026. It's the second major pharma bet on psychedelic-adjacent chemistry disclosed in 2026, following Lilly's AtaiBeckley deal, underscoring how quickly the category has moved from fringe interest to mainstream pharma pipelines. The deal was completed in June 2026.

‍

‍

‍

Top Precision Medicine IPOs (By Value)

1 | Parabilis Medicines IPO ($670M Raised) | Biotech

Parabilis Medicines (formerly Fog Pharmaceuticals) priced its IPO at $20 per share, raising $670 million in the largest biotech IPO in history. The Cambridge, Massachusetts-based company develops “Helicon” peptides engineered to bind previously undruggable protein targets, with proceeds earmarked for a Phase 3 push in desmoid tumors and continued early-stage work across other solid-tumor indications. Regeneron participated in a concurrent private placement alongside the public offering. Shares began trading June 10, 2026, on the Nasdaq under the ticker PBLS.

2 | Kailera Therapeutics IPO ($625M Raised) | Biotech

Kailera Therapeutics, a clinical-stage obesity drug developer, raised $625 million in an upsized IPO priced at $16 per share, the sector's biggest US listing since 2021. Shares surged 63% on debut, closing at $26. The Waltham, Massachusetts-based company is positioning itself as a challenger to Novo Nordisk and Eli Lilly in the obesity market, with a pipeline built on assets licensed from Hengrui Pharmaceuticals.

3 | Eikon Therapeutics IPO (up to ~$401M Raised) | Biotech

Eikon Therapeutics, a clinical-stage biotechnology company developing live-cell super-resolution microscopy to enable drug discovery and precision medicines, priced its upsized IPO at $22 per share, raising approximately $351 million in gross proceeds, with the potential to reach ~$401 million if underwriters fully exercised their option. Shares debuted strongly on the Nasdaq under the ticker EIKN, reflecting continued investor appetite for well-capitalized, platform-driven biotech companies with differentiated technology and advancing clinical pipelines.

4 | Aktis Oncology IPO ($318M Raised) | Biotech

Aktis Oncology, a radiopharmaceutical developer, opened 2026's IPO market with an upsized offering that raised $318 million at $18 per share, with underwriters fully exercising their option for additional shares. Shares jumped 27% in early trading. As the first sizable biotech listing of the year, the deal set an encouraging tone for the IPO window heading into 2026.

5 | Odyssey Therapeutics IPO ($304M Raised) | Biotech

Odyssey Therapeutics, an autoimmune and inflammatory disease drug developer, raised approximately $304 million in an upsized IPO and concurrent private placement, pricing shares at $18. TPG Life Sciences Innovations participated in the concurrent private placement alongside the public offering. The listing marked a successful second attempt at going public for the six-year-old company.

6 | Alamar Biosciences IPO (up to $219.9M Raised) | Biotech

Alamar Biosciences, a precision-proteomics platform developer, priced an upsized IPO at $17 per share, raising roughly $191 million in gross proceeds with potential for up to $219.9 million including the underwriters' option. Shares opened at $22, up nearly 30%, on the Nasdaq under ticker ALMR. The listing extended a run of AI- and platform-driven diagnostics companies finding a receptive public market in 2026.

‍

‍

‍

Major Private Equity & Venture Capital Activity

1 | Blackstone Closes Record $6.3B Life Sciences Fund | PE

Blackstone closed a record $6.3 billion life sciences fund with Blackstone Life Sciences VI, 40% larger than its predecessor and the largest private fund ever dedicated to life sciences investing. The fund will continue deploying capital into late-stage oncology, autoimmune disease, RNA therapeutics, and gene medicine assets; the strategy's existing portfolio has produced an 86% regulatory approval rate, well above the industry average. The close, in March 2026, underscored continued institutional conviction in life sciences even as public biotech valuations remained selective.

2 | Blackstone Life Sciences Invests $250M in Anagram Therapeutics | PE

Blackstone Life Sciences invested $250 million in Anagram Therapeutics to fund development of ANG003, an oral recombinant enzyme replacement therapy for pancreatic insufficiency. The structured investment reflects Blackstone's model of providing late-stage development capital in exchange for milestone- and royalty-based returns rather than equity alone. The deal, announced in May 2026, was one of the first major deployments from the newly closed Fund VI.

3 | Santé Ventures Closes $330M Fund V | VC

Santé Ventures closed its fifth fund at $330 million, exceeding its $300 million target and marking the Austin-based firm's largest fund to date. Fund V will continue Santé's focus on early-stage biotech, medtech, and digitally enabled healthcare companies. The close, announced February 2, 2026, came alongside the promotion of two long-time team members to managing director, reflecting a broadening of the firm's investment leadership.